Alector Inc

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alector Inc reports robust earnings, advances Alzheimer's therapy development

Alector Inc's Q2 2023 earnings call highlighted strong financial performance, progress in late-stage clinical programs, and a focus on immuno-neurology research.
The company faces challenges in trial management and disease progression variability but benefits from a solid cash position and collaboration revenue.
Opportunities lie in upcoming milestones, conference participation, and the potential of AL002 therapy, positioning Alector for continued growth and innovation.

Alector Inc reports strong Q4 performance and advances in neurodegenerative treatments

Alector Inc's Q4 performance reflects significant achievements in late-stage programs, strong financial standing, and positive patient engagement, underlining progress in neurodegenerative disease treatment.
The company's strengths in immuno-neurology, blood-brain barrier technology, and strategic partnerships position them well for addressing Alzheimer's disease and exploring accelerated approval pathways.
Challenges in trial design, biomarker assessment, and resource allocation require careful navigation, while opportunities in therapeutic delivery enhancement and disease progression slowing offer avenues for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In connection with the proposed offering, Alector expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of its common stock offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. All of the shares in the proposed offering are being sold by Alector.

Alector Announces Proposed Public Offering of Common Stock

Alector's stock has traded mostly sideways, down 18% from last year, despite having a promising late-stage CNS pipeline, loads of cash, and two big partnerships. The company has trimmed down its pipeline from 9 programs to 3, but this is a good thing. Alector's latest news is scarce, with no recent press releases or updates, leading to a lack of catalysts for the stock in the next few quarters.

Alector: Good Data, Huge Cash, No Near Term Catalyst

The average of price targets set by Wall Street analysts indicates a potential upside of 142.5% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet

AbbVie

Amylyx Pharmaceuticals

Athira Pharma

Coya Therapeutics Inc

GlaxoSmithKline

Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.

These biotechs targeting multiple neurodegenerative diseases

Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 11:30 a.m. ET.

Alector to Participate in the Stifel Healthcare Conference

Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has achieved target enrollment in INFRONT-3, the pivotal Phase 3 clinical trial of latozinemab (AL001). INFRONT-3 is evaluating the safety and efficacy of latozinemab in slowing disease progression in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). Latozinemab is an investigational human monoclonal antibody designed to block sortilin, a degradation receptor for progranulin (PGRN). It is intended to elevate PGRN levels and enhance the activity of microglia, the primary cells of the brain's innate immune system. Latozinemab is the most advanced PGRN modulating product candidate in clinical trials and the most advanced potential treatment for FTD-GRN. Latozinemab is being developed in collaboration with GSK.

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.

Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study

The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade

Alector, Inc. (NASDAQ:ALEC ) Q2 2023 Results Conference Call August 3, 2023 4:30 PM ET Company Participants Katie Hogan - Senior Director of Corporate Communication and Investor Relations Dr. Arnon Rosenthal - Co-Founder and CEO Dr. Sara Kenkare-Mitra - President and Head of Research and Development Dr. Gary Romano - Chief Medical Officer Dr. Marc Grasso - Chief Financial Officer. Conference Call Participants Graig Suvannavejh - Mizuho Securities Paul Matteis - Stifel Tom Shrader - BTIG Myles Minter - William Blair Operator Good afternoon, ladies and gentlemen, and welcome to the Alector Midyear 2023 Earnings Conference Call.

Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript

Alector (ALEC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to earnings of $0.12 per share a year ago.

Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates

Asana

Okta

Teladoc

Twilio

Unity Software

Artificial intelligence technology is transforming many industries and creating new opportunities for businesses and consumers. But as an investor, how can you benefit from this powerful technology?

7 Stocks That AI Says Will Make You a Millionaire by 2025

SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 10:40 a.m. PT.

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

The consensus price target hints at an 86.4% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect?

On track to engage with regulatory authorities on the pivotal Phase 3 INFRONT-3 clinical trial of latozinemab in mid-2023; targeting data readout in early 2025

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a corporate presentation at the BofA Securities 2023 Healthcare Conference in Las Vegas on Wednesday, May 10, 2023, at 2:20 p.m. PT.

Alector to Participate in the BofA Securities 2023 Healthcare Conference

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for

On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer's disease in Q3 2023, with data readout expected by Q4 2024

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alector (ALEC) Expected to Beat Earnings Estimates: Should You Buy?

Alector, Inc. has a lot of cash for a small biotech, but it is also trading at cash. Alector, Inc. has a late-stage program in a CNS indication and major big pharma deals.

Alector: Trading At Cash Despite Late Stage CNS Pipeline

SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on December 6, 2022, the compensation committee of Alector's board of directors granted 8 (eight)  new employees options to purchase an aggregate of 91,851 shares of the company's common stock and restricted stock units (RSUs) for an aggregate of 40,961 shares of the company's common stock. These awards are made under Alector's 2022 Inducement Equity Incentive Plan (the “Plan”).

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer's disease

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Alector Inc Stock (ALEC)